SyntekaBio
신테카바이오 · 226330
Information Technology Software · KOSDAQ
Market cap US$35.2M (₩48.5B)
Overview
SyntekaBio uses artificial intelligence to help drug researchers find and refine promising drug candidates faster, its platforms analyse three-dimensional protein structures and large-scale genomic data to screen compounds and identify targets.
Listed on KOSDAQ, Korea's tech-focused stock exchange, it supplies these AI-driven drug-discovery services to pharmaceutical and biotech clients, and its genomic precision-medicine platform is already generating revenue through domestic university hospitals. Its own internal drug pipeline, covering synthetic drugs, drug repurposing, and antibody therapies, runs alongside the platform services business.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$89.4K
- FY2024US$87.6K
- FY2025US$2.5M
Operating profit
- FY2023−US$8.9M
- FY2024−US$10.3M
- FY2025−US$7.8M
Net income
- FY2023−US$8.3M
- FY2024−US$5.2M
- FY2025−US$12.6M
Key ratios (FY2025)
Why it matters
SyntekaBio's supercomputing and big-data infrastructure originated partly through a technology contribution from ETRI, Korea's state-run electronics and telecommunications research institute.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?